{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:06:06Z","timestamp":1792706766395,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.pcad.2024.02.001","type":"journal-article","created":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T05:07:57Z","timestamp":1707800877000},"page":"62-68","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["Real-world experience with mavacamten in obstructive hypertrophic cardiomyopathy: Observations from a tertiary care center"],"prefix":"10.1016","volume":"86","author":[{"given":"Milind Y.","family":"Desai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adel","family":"Hajj-Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katy","family":"Rutkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Ospina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Gaballa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Emery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Asher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maran","family":"Thamilarasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoran B.","family":"Popovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.pcad.2024.02.001_bb0005","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1161\/01.CIR.92.4.785","article-title":"Prevalence of hypertrophic cardiomyopathy in a general population of young adults: echocardiographic analysis of 4111 subjects in the CARDIA study","volume":"92","author":"Maron","year":"1995","journal-title":"Circulation."},{"issue":"4","key":"10.1016\/j.pcad.2024.02.001_bb0010","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1056\/NEJMoa021332","article-title":"Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy","volume":"348","author":"Maron","year":"2003","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.pcad.2024.02.001_bb0015","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1093\/eurheartj\/ehl041","article-title":"Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy","volume":"27","author":"Elliott","year":"2006","journal-title":"Eur Heart J"},{"issue":"25","key":"10.1016\/j.pcad.2024.02.001_bb0020","article-title":"AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"76","author":"Ommen","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"37","key":"10.1016\/j.pcad.2024.02.001_bb0025","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"ESC guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.pcad.2024.02.001_bb0030","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2174\/1573403X1201160126125403","article-title":"Drug therapy for hypertrophic Cardiomypathy: physiology and practice","volume":"12","author":"Sherrid","year":"2016","journal-title":"Curr Cardiol Rev"},{"issue":"16","key":"10.1016\/j.pcad.2024.02.001_bb0035","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.jacc.2022.02.024","article-title":"Effects of metoprolol on exercise hemodynamics in patients with obstructive hypertrophic cardiomyopathy","volume":"79","author":"Dybro","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.pcad.2024.02.001_bb0040","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2005.02.090","article-title":"Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy","volume":"46","author":"Ommen","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.pcad.2024.02.001_bb0045","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.athoracsur.2007.07.063","article-title":"Current effectiveness and risks of isolated septal myectomy for hypertrophic obstructive cardiomyopathy","volume":"85","author":"Smedira","year":"2008","journal-title":"Ann Thorac Surg"},{"issue":"16","key":"10.1016\/j.pcad.2024.02.001_bb0050","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1161\/01.CIR.0000162460.36735.71","article-title":"Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy","volume":"111","author":"Woo","year":"2005","journal-title":"Circulation"},{"issue":"22","key":"10.1016\/j.pcad.2024.02.001_bb0055","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1016\/j.jacc.2011.08.040","article-title":"Long-term survival in patients with resting obstructive hypertrophic cardiomyopathy comparison of conservative versus invasive treatment","volume":"58","author":"Ball","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.pcad.2024.02.001_bb0060","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1161\/CIRCULATIONAHA.112.000849","article-title":"Predictors of long-term outcomes in symptomatic hypertrophic obstructive cardiomyopathy patients undergoing surgical relief of left ventricular outflow tract obstruction","volume":"128","author":"Desai","year":"2013","journal-title":"Circulation."},{"issue":"1","key":"10.1016\/j.pcad.2024.02.001_bb0065","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.016210","article-title":"Outcomes in guideline-based class I indication versus earlier referral for surgical Myectomy in hypertrophic obstructive cardiomyopathy","volume":"10","author":"Alashi","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"10.1016\/j.pcad.2024.02.001_bb0070","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1016\/j.athoracsur.2020.09.011","article-title":"Late health status of patients undergoing Myectomy for obstructive hypertrophic cardiomyopathy","volume":"111","author":"Nguyen","year":"2021","journal-title":"Ann Thorac Surg"},{"issue":"4","key":"10.1016\/j.pcad.2024.02.001_bb0075","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jacc.2021.11.021","article-title":"Management of hypertrophic cardiomyopathy: JACC State-of-the-Art review","volume":"79","author":"Maron","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.pcad.2024.02.001_bb0080","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/j.amjcard.2014.07.075","article-title":"Results of ventricular septal myectomy and hypertrophic cardiomyopathy (from Nationwide inpatient sample [1998-2010])","volume":"114","author":"Panaich","year":"2014","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.pcad.2024.02.001_bb0085","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamacardio.2016.0252","article-title":"Hospital volume outcomes after septal myectomy and alcohol septal ablation for treatment of obstructive hypertrophic cardiomyopathy: US Nationwide Inpatient Database, 2003\u20132011","volume":"1","author":"Kim","year":"2016","journal-title":"JAMA Cardiol"},{"issue":"10253","key":"10.1016\/j.pcad.2024.02.001_bb0090","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet."},{"issue":"1","key":"10.1016\/j.pcad.2024.02.001_bb0095","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jchf.2023.09.028","article-title":"Mavacamten treatment for symptomatic obstructive hypertrophic cardiomyopathy: interim results from the MAVA-LTE study, EXPLORER-LTE cohort","volume":"12","author":"Rader","year":"2024","journal-title":"JACC Heart Fail"},{"issue":"2","key":"10.1016\/j.pcad.2024.02.001_bb0100","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","article-title":"Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy","volume":"80","author":"Desai","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.pcad.2024.02.001_bb0105","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1161\/CIRCULATIONAHA.122.062534","article-title":"Dose-blinded myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy: outcomes through 32 Weeks","volume":"147","author":"Desai","year":"2023","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.pcad.2024.02.001_bb0110","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1001\/jamacardio.2023.3342","article-title":"Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: week 56 results from the VALOR-HCM randomized clinical trial","volume":"8","author":"Desai","year":"2023","journal-title":"JAMA Cardiol"},{"issue":"9","key":"10.1016\/j.pcad.2024.02.001_bb0115","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.echo.2023.04.020","article-title":"A practical approach to echocardiographic imaging in patients with hypertrophic cardiomyopathy","volume":"36","author":"Mitchell","year":"2023","journal-title":"J Am Soc Echocardiogr"},{"issue":"6","key":"10.1016\/j.pcad.2024.02.001_bb0120","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.echo.2022.03.012","volume":"35","author":"Nagueh","year":"2022","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.pcad.2024.02.001_bb0130","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ahj.2021.05.007","article-title":"Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy","volume":"239","author":"Desai","year":"2021","journal-title":"Am Heart J"},{"key":"10.1016\/j.pcad.2024.02.001_bb0135","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.pcad.2023.06.001","article-title":"Patient reported outcomes in obstructive hypertrophic cardiomyopathy undergoing myectomy: results from SPIRIT-HCM study","volume":"80","author":"Tower-Rader","year":"2023","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.pcad.2024.02.001_bb0140","series-title":"One-year real-world experience with mavacamten and its physiologic effects on obstructive hypertrophic cardiomyopathy","author":"Kim","year":"2023"},{"issue":"10","key":"10.1016\/j.pcad.2024.02.001_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2023.100710","article-title":"Mavacamten short-term hemodynamic, functional, and electrocardiographic outcomes","volume":"2","author":"Abdelfattah","year":"2023","journal-title":"JACC Adv"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062024000227?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062024000227?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T22:11:30Z","timestamp":1738188690000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062024000227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":28,"alternative-id":["S0033062024000227"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2024.02.001","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world experience with mavacamten in obstructive hypertrophic cardiomyopathy: Observations from a tertiary care center","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2024.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}